| 1. |
Jeganathan R, Armstrong S, Al-Alao B, et al. The risk and outcomes of reoperative tricuspid valve surgery. Ann Thorac Surg, 2013, 95(1): 119-124.
|
| 2. |
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 143(5): e72-e227.
|
| 3. |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
|
| 4. |
Gammie JS, Chu MWA, Falk V, et al. Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med, 2022, 386(4): 327-339.
|
| 5. |
Chikwe J, Gaudino M. The price of freedom from tricuspid regurgitation. N Engl J Med, 2022, 386(4): 389-390.
|
| 6. |
Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011, 124(23): e652-e735.
|
| 7. |
Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: A scientific statement from the American Heart Association. Circulation, 2015, 131(10): 927-964.
|
| 8. |
Yahagi K, Kolodgie FD, Otsuka F, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol, 2016, 13(2): 79-98.
|
| 9. |
Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: A randomized clinical trial. JAMA, 2018, 319(16): 1677-1686.
|
| 10. |
Gaudino M, Di Franco A, Bhatt DL, et al. The association between coronary graft patency and clinical status in patients with coronary artery disease. Eur Heart J, 2021, 42(14): 1433-1441.
|
| 11. |
Schunkert H, Boening A, von Scheidt M, et al. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: The TiCAB trial. Eur Heart J, 2019, 40(29): 2432-2440.
|
| 12. |
Willemsen LM, Janssen PWA, Peper J, et al. Effect of adding ticagrelor to standard aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (POPular CABG): A randomized, double-blind, placebo-controlled trial. Circulation, 2020, 142(19): 1799-1807.
|
| 13. |
Saw J, Wong GC, Mayo J, et al. Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. Heart, 2016, 102(10): 763-769.
|
| 14. |
Tian M, Wang X, Sun H, et al. No-touch versus conventional vein harvesting techniques at 12 months after coronary artery bypass grafting surgery: Multicenter randomized, controlled trial. Circulation, 2021, 144(14): 1120-1129.
|
| 15. |
Taggart DP, Altman DG, Gray AM, et al. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med, 2016, 375(26): 2540-2549.
|
| 16. |
Gaudino M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med, 2018, 378(22): 2069-2077.
|
| 17. |
Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J, 2021, 42(14): 1289-1367.
|
| 18. |
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation, 2016, 134(10): e123-e155.
|
| 19. |
Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol, 2018, 72(23 Pt A): 2915-2931.
|
| 20. |
Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol, 2018, 34(3): 214-233.
|
| 21. |
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018, 39(3): 213-260.
|
| 22. |
Nakashima CAK, Dallan LAO, Lisboa LAF, et al. Platelet reactivity in patients with acute coronary syndromes awaiting surgical revascularization. J Am Coll Cardiol, 2021, 77(10): 1277-1286.
|
